What is it about?
Hypertriglyceridemia signalizes an increased number of small dense low density lipoprotein (sd LDL) particles that are highly atherogenic, and predictive of cardiovascular (CV) events. This review focuses on the common causes and consequences of high triglyceride (TG) levels, discusses diagnostic work-up and therapeutic options, and presents some key points from current guidelines for the management of dyslipidemias and CV risk.
Featured Image
Why is it important?
The beneficial impact of pharmaceutical care (PC) interventions on clinical outcomes among patients with dyslipidemia and CV risk underlines the importance of cooperation between physicians and pharmacists, in successful managing of patients with lipid disorders (e.g., selection of lipid-modifying medications, based on their effectiveness, safety, and clinical context).
Perspectives
Medical practitioners can use easily available tools, which greatly facilitate an assessment of patients with atherogenic dyslipidemia (e.g.: in case of central obesity, insulin resistance, metabolic syndrome, pre-diabetes, or diabetes), and elevated CV risk. They include measurements of non-high density lipoprotein – cholesterol (non-HDL-C) and TG/HDL-C ratio.
Katarzyna Rygiel
Read the Original
This page is a summary of: Hypertriglyceridemia - Common Causes, Prevention and treatment Strategies, Current Cardiology Reviews, March 2018, Bentham Science Publishers,
DOI: 10.2174/1573403x14666180123165542.
You can read the full text:
Contributors
The following have contributed to this page
